Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis

Journal of the National Cancer Institute

Volumn 97, Issue 3, 2005, Pages 188-194

  Mauri, Davide ^a   Pavlidis, Nicholas ^a   Ioannidis, John P A ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; FORMESTANE; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN; MITOXANTRONE; TAMOXIFEN; THIOTEPA; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE COURSE; EMBASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTECTOMY; MEDLINE; META ANALYSIS; PARTIAL MASTECTOMY; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; NEOADJUVANT THERAPY; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 13744257860     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji021     Document Type: Article

References (44)

1. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003;98:1150-60.
2. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-32.
3. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
4. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347:567-75.
5. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-92.
6. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001.
7. Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 1989;49:2002-4.
8. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
9. Avril A, Faucher A, Bussieres E, Stockle E, Durand M, Mauriac L, et al. Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3 cm. Chirurgie 1998;123:247-56. [In French.]
10. Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
11. Semiglazov VF, Topuzov EE, Bavli JL, Moiseyenko VM, Ivanova OA, Seleznev IK, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 1994;5:591-5.
12. Scholl SM, Asselain B, Palangie T, Dorval T, Jouve M, Garcia Giralt E, et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 1991;27:1668-71.
13. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-52.
14. Broet P, Scholl SM, de la Rochefordiere A, Fourquet A, Moreau T, De Rycke Y, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 1999;58:151-6.
15. Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA, et al. A reduction in the requirements for mastectomy in a randomized trial of ncoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-84.
16. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85.
17. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
18. Gazet JC, Ford HT, Gray R, McConkey C, Sutcliffe R, Quilliam J, et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 2001;12:685-91.
19. Danforth DN Jr, Cowan K, Altemus R, Merino M, Chow C, Berman A, et al. Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial. Ann Surg Oncol 2003;10:635-44.
20. Ragaz J. Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy. NCI Monogr 1986;1:145-52.
21. Ragaz J. Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia Trial. Recent Results Cancer Res 1986;103:85-94.
22. Ragaz J, Baird R, Rebbeck P, Coldman A, Goldie J. Neoadjuvant-preoperative-chemotherapy for breast cancer - preliminary report of the Vancouver trial. Prog Clin Biol Res 1985;201:77-87.
23. Jakesz R, for ABCSG. Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: Four-years results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. Proc Am Soc Clin Oncol 2001;20:125.
24. Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Garcia-Conde J, et al. First report of the European Cooperative Trial in Operable Breast Cancer (ECTO): Effects of primary systemic therapy (PST) on loco-regional disease. Proc Am Soc Clin Oncol 2002;21:34a.
25. Grossi F, Belvedere O, Rosso R: Geography of clinical cancer research publications from 1995 to 1999. Eur J Cancer 2003;39:106-11.
26. Hopewell S, Clarke M, Lusher A, Lefebvre C, Westby M. A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials. Stat Med 2002;21:1625-34.
27. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
29. Ioannidis JP, Contopoulos-Ioannidis DG, Lau J. Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. J Clin Epidemiol 1999;52:281-91.
30. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001;98:831-6.
31. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-8.
32. Aas T, Geisler S, Eide GE, Haugen DF, Varhaug JE, Bassoe AM, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003;39:438-46.
33. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997;349:849.
34. Shao ZM, Li J, Wu J, Han QX, Shen ZZ, Fontana JA, Barsky SH. Neoadjuvant chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat 1999;53:263-9.
35. von Minckwitz G, Raab G, Shutte M, Hilfrich J, Blohmer JU, Gerber B, et al. Dose-dense versus sequential Adriamycin/docetaxel combination as preoperative chemotheraphy (pCHT) in operable breast cancer (T2-3 N0-2 M0): Primary endpoint analysis of the GEPARDUO study. Proc Am Soc Clin Oncol 2002;21:43a.
36. NSABP: The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results of the NSABP protocol B-27. Breast Canc Res Treat 2001;69:210.
37. Pierga JY, Mouret E, Dieras V, Laurence V, Beuzeboc P, Dorval T, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83: 1480-7.
38. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002;25:76-97.
39. Clarke M, Stewart L, Pignon JP, Bijnens L. Individual patient data meta-analysis in cancer. Br J Cancer 1998;77:2036-44.
40. Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 2001;54:245-52.
41. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998;351:123-7.
42. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-66.
43. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.
44. Buzdar AU, Hunt K, Smith T, Francis D, Ewer D, Booser E, et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P) and antracycline-containing chemotherapy (CT): initial results of a randomised trial in operable breast cancer (BC) with HER/2 positive disease. New Orleans, LA: Proc ASCO, 2004 June 5-8. Proc Am Soc Clin Oncol 2004;23:7.